Literature DB >> 10935475

"...those left behind." Biology and oncology of invasive glioma cells.

M E Berens1, A Giese.   

Abstract

Although significant technical advances in surgical and radiation treatment for brain tumors have emerged in recent years, their impact on clinical outcome for patients has been disappointing. A fundamental source of the management challenge presented by glioma patients is the insidious propensity of the malignant cells to invade into adjacent normal brain. Invasive tumor cells escape surgical removal and geographically dodge lethal radiation exposure. Recent improved understanding of the biochemistry and molecular determinants of glioma cell invasion provide valuable insight to the underlying biological features of the disease, as well as illuminating possible new therapeutic targets. Heightened commitment to migrate and invade is accompanied by a glioma cell's reduced proliferative activity. The microenvironmental manipulations coincident to invasion and migration may also impact the glioma cell's response to cytotoxic treatments. These collateral aspects of the glioma cell invasive phenotype should be further explored and exploited as novel antiglioma therapies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10935475      PMCID: PMC1508082          DOI: 10.1038/sj.neo.7900034

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  163 in total

1.  CD44 is involved in migration but not spreading of astrocytoma cells in vitro.

Authors:  B Radotra; D McCormick
Journal:  Anticancer Res       Date:  1997 Mar-Apr       Impact factor: 2.480

2.  Isolation and characterization of human malignant glioma cells from histologically normal brain.

Authors:  D L Silbergeld; M R Chicoine
Journal:  J Neurosurg       Date:  1997-03       Impact factor: 5.115

3.  Cell proliferation and invasion in malignant gliomas.

Authors:  D Schiffer; P Cavalla; A Dutto; L Borsotti
Journal:  Anticancer Res       Date:  1997 Jan-Feb       Impact factor: 2.480

Review 4.  Stem cells in the central nervous system.

Authors:  R McKay
Journal:  Science       Date:  1997-04-04       Impact factor: 47.728

5.  The role of the extracellular matrix in neoplastic glial invasion of the nervous system.

Authors:  C J Pilkington
Journal:  Braz J Med Biol Res       Date:  1996-09       Impact factor: 2.590

6.  Role of high molecular weight extracellular matrix proteins in glioma cell migration.

Authors:  R Mahesparan; B B Tysnes; K Edvardsen; H K Haugeland; I G Cabrera; M Lund-Johansen; O Engebraaten; R Bjerkvig
Journal:  Neuropathol Appl Neurobiol       Date:  1997-04       Impact factor: 8.090

Review 7.  A molecular genetic model of astrocytoma histopathology.

Authors:  D N Louis
Journal:  Brain Pathol       Date:  1997-04       Impact factor: 6.508

8.  Fibronectin-mediated cell migration promotes glioma cell invasion through chemokinetic activity.

Authors:  T Ohnishi; N Arita; S Hiraga; T Taki; S Izumoto; Y Fukushima; T Hayakawa
Journal:  Clin Exp Metastasis       Date:  1997-09       Impact factor: 5.150

9.  Inhibitory effects of CAI in glioblastoma growth and invasion.

Authors:  W Jacobs; T Mikkelsen; R Smith; K Nelson; M L Rosenblum; E C Kohn
Journal:  J Neurooncol       Date:  1997-04       Impact factor: 4.130

Review 10.  Hyaluronan in morphogenesis.

Authors:  B P Toole
Journal:  J Intern Med       Date:  1997-07       Impact factor: 8.989

View more
  55 in total

1.  Fibulin-3 promotes glioma growth and resistance through a novel paracrine regulation of Notch signaling.

Authors:  Bin Hu; Mohan S Nandhu; Hosung Sim; Paula A Agudelo-Garcia; Joshua C Saldivar; Claire E Dolan; Maria E Mora; Gerard J Nuovo; Susan E Cole; Mariano S Viapiano
Journal:  Cancer Res       Date:  2012-06-04       Impact factor: 12.701

2.  Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.

Authors:  Morris D Groves; Vinay K Puduvalli; Charles A Conrad; Mark R Gilbert; W K Alfred Yung; Kurt Jaeckle; Vivien Liu; Kenneth R Hess; Kenneth D Aldape; Victor A Levin
Journal:  J Neurooncol       Date:  2006-04-25       Impact factor: 4.130

3.  CNS Anticancer Drug Discovery and Development Conference White Paper.

Authors:  Victor A Levin; Peter J Tonge; James M Gallo; Marc R Birtwistle; Arvin C Dar; Antonio Iavarone; Patrick J Paddison; Timothy P Heffron; William F Elmquist; Jean E Lachowicz; Ted W Johnson; Forest M White; Joohee Sul; Quentin R Smith; Wang Shen; Jann N Sarkaria; Ramakrishna Samala; Patrick Y Wen; Donald A Berry; Russell C Petter
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

Review 4.  The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas.

Authors:  Florence Lefranc; Robert Kiss
Journal:  Neoplasia       Date:  2008-03       Impact factor: 5.715

5.  Regulation of the leucocyte chemoattractant receptor FPR in glioblastoma cells by cell differentiation.

Authors:  Jian Huang; Keqiang Chen; Jiaqiang Huang; Wanghua Gong; Nancy M Dunlop; O M Zack Howard; Xiuwu Bian; Yuqi Gao; Ji Ming Wang
Journal:  Carcinogenesis       Date:  2008-11-26       Impact factor: 4.944

6.  Definition of K(trans) and FA thresholds for better assessment of experimental glioma using high-field MRI: a feasibility study.

Authors:  T Engelhorn; M A Schwarz; A Hess; L Budinsky; P Pitann; I Eyüpoglu; A Doerfler
Journal:  Clin Neuroradiol       Date:  2013-12-18       Impact factor: 3.649

Review 7.  Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression.

Authors:  J Carlsson; Z P Ren; K Wester; A L Sundberg; N E Heldin; G Hesselager; M Persson; L Gedda; V Tolmachev; H Lundqvist; E Blomquist; M Nistér
Journal:  J Neurooncol       Date:  2006-03       Impact factor: 4.130

Review 8.  Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.

Authors:  Sagar Agarwal; Ramola Sane; Rajneet Oberoi; John R Ohlfest; William F Elmquist
Journal:  Expert Rev Mol Med       Date:  2011-05-13       Impact factor: 5.600

9.  The lectin concanavalin-A signals MT1-MMP catalytic independent induction of COX-2 through an IKKgamma/NF-kappaB-dependent pathway.

Authors:  Asmaa Sina; Sébastien Proulx-Bonneau; Alain Roy; Laurent Poliquin; Jian Cao; Borhane Annabi
Journal:  J Cell Commun Signal       Date:  2010-01-27       Impact factor: 5.782

Review 10.  Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics.

Authors:  Camilla Krakstad; Martha Chekenya
Journal:  Mol Cancer       Date:  2010-06-01       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.